Literature DB >> 14563800

Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect.

Treena Livingston Arinzeh1, Susan J Peter, Michael P Archambault, Christian van den Bos, Steve Gordon, Karl Kraus, Alan Smith, Sudha Kadiyala.   

Abstract

BACKGROUND: Mesenchymal stem cells from adult bone marrow are multipotent cells capable of forming bone, cartilage, and other connective tissues. In a previous study, we demonstrated that autologous mesenchymal stem cells could repair a critical-sized bone defect in the dog. The objective of this study was to determine whether the use of allogeneic mesenchymal stem cells could heal a critical-sized bone defect in the femoral diaphysis in dogs without the use of immunosuppressive therapy.
METHODS: A critical-sized segmental bone defect, 21 mm in length, was created in the mid-portion of the femoral diaphysis of twelve adult dogs that weighed between 22 and 25 kg. Each defect was treated with allogeneic mesenchymal stem cells loaded onto a hollow ceramic cylinder consisting of hydroxyapatite-tricalcium phosphate. A complete mismatch between donor stem cells and recipient dogs was identified by dog leukocyte antigen typing prior to implantation. The healing response was evaluated histologically and radiographically at four, eight, and sixteen weeks after implantation. The radiographic and histological results at sixteen weeks were compared with the historical data for the control defects, which included defects that had been treated with a cylinder loaded with autologous mesenchymal stem cells, defects treated with a cylinder without mesenchymal stem cells, and defects that had been left untreated (empty). The systemic immune response was evaluated by the analysis of recipient serum for production of antibodies against allogeneic cells.
RESULTS: For defects treated with allogeneic mesenchymal stem cell implants, no adverse host response could be detected at any time-point. Histologically, no lymphocytic infiltration occurred and no antibodies against allogeneic cells were detected. Histologically, by eight weeks, a callus spanned the length of the defect, and lamellar bone filled the pores of the implant at the host bone-implant interface. Fluorescently labeled allogeneic cells were also detected. At sixteen weeks, new bone had formed throughout the implant. These results were consistent with those seen in implants loaded with autologous cells. Implants loaded with allogeneic or autologous stem cells had significantly greater amounts of bone within the available pore space than did cell-free implants at sixteen weeks (p < 0.05).
CONCLUSIONS: The results of this study demonstrated that allogeneic mesenchymal stem cells loaded on hydroxyapatite-tricalcium phosphate implants enhanced the repair of a critical-sized segmental defect in the canine femur without the use of immunosuppressive therapy. No adverse immune response was detected in this model.

Entities:  

Mesh:

Year:  2003        PMID: 14563800     DOI: 10.2106/00004623-200310000-00010

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  104 in total

Review 1.  Comprehensive review of the clinical application of autologous mesenchymal stem cells in the treatment of chronic wounds and diabetic bone healing.

Authors:  Gerit D Mulder; Daniel K Lee; Nathan S Jeppesen
Journal:  Int Wound J       Date:  2012-02-28       Impact factor: 3.315

Review 2.  Mesenchymal stem cells: lineage, plasticity, and skeletal therapeutic potential.

Authors:  Richard O C Oreffo; Cyrus Cooper; Christopher Mason; Mark Clements
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

3.  Sol-gel method to fabricate CaP scaffolds by robocasting for tissue engineering.

Authors:  Manuel Houmard; Qiang Fu; Eduardo Saiz; Antoni P Tomsia
Journal:  J Mater Sci Mater Med       Date:  2012-02-07       Impact factor: 3.896

4.  Effects of ectopic Nanog and Oct4 overexpression on mesenchymal stem cells.

Authors:  Tong Ming Liu; Ying Nan Wu; Xi Min Guo; James Hoi Po Hui; Eng Hin Lee; Bing Lim
Journal:  Stem Cells Dev       Date:  2009-09       Impact factor: 3.272

Review 5.  Immunomodulation by mesenchymal stem cells in veterinary species.

Authors:  Danielle D Carrade; Dori L Borjesson
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

6.  Characterization and differentiation potential of rabbit mesenchymal stem cells for translational regenerative medicine.

Authors:  A Bakhtina; M Tohfafarosh; A Lichtler; T Livingston Arinzeh
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-10-23       Impact factor: 2.416

7.  Mesenchymal progenitor cells derived from traumatized human muscle.

Authors:  W M Jackson; A B Aragon; F Djouad; Y Song; S M Koehler; L J Nesti; R S Tuan
Journal:  J Tissue Eng Regen Med       Date:  2009-02       Impact factor: 3.963

8.  Rapid prototyping for tissue-engineered bone scaffold by 3D printing and biocompatibility study.

Authors:  Hui-Yu He; Jia-Yu Zhang; Xue Mi; Yang Hu; Xiao-Yu Gu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

9.  Cell-based therapies for regenerating bone.

Authors:  S B Goodman
Journal:  Minerva Ortop Traumatol       Date:  2013-04-01

10.  Amide-type local anesthetics and human mesenchymal stem cells: clinical implications for stem cell therapy.

Authors:  Ryan C Dregalla; Nicolette F Lyons; Patrick D Reischling; Christopher J Centeno
Journal:  Stem Cells Transl Med       Date:  2014-01-16       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.